Hu, Tianyan
Podmore, Bélène
Barnett, Rosemarie
Beier, Dominik
Galetzka, Wolfgang
Qizilbash, Nawab
Heckl, Dennis
Boellinger, Timo
Weaver, Jessica
Funding for this research was provided by:
Merck
Article History
Received: 13 October 2022
Accepted: 5 January 2023
First Online: 25 March 2023
Declarations
:
: All patient-level data in the InGef research database are de-identified to comply with German data protection regulations. Use of the study database for healthcare services research is therefore fully compliant with German federal law and, accordingly, Institutional Review Board or ethical approval for this study was not needed. Since this study was based on anonymized claims data, no informed consent of the patient was required.
: Not applicable.
: This research was sponsored and funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD). OXON Epidemiology, an independent contract research organization, was contracted by MSD to design and conduct the study in collaboration with WIG2. InGef acted as subcontractor and received funding from WIG2 for the execution of the study. All authors declare financial and non-financial conflicts of interest. JW is employed by MSD, and TB is employed by MSD Sharp & Dohme GmbH, Germany. TH was employed by MSD at the time of this study. BP, RB and NQ are employed by OXON Epidemiology. DH is employed by WIG2. DB is employed by InGef and WG was employed by InGef at the time of this study.